These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1690744)

  • 21. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
    Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
    J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine].
    Takayama N; Kidokoro M; Suzuki K; Morita M
    Kansenshogaku Zasshi; 1992 Jun; 66(6):776-80. PubMed ID: 1331262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
    Narayan KM; Moffat MA
    Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies.
    Makino S; Sasaki K; Nakayama T; Oka S; Urano T; Kimura M; Kawana R; Yamamura AM
    Am J Dis Child; 1990 Aug; 144(8):905-10. PubMed ID: 2198807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measles, mumps, and rubella antibodies in vaccinated Baltimore children.
    King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J
    Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of pestivirus RNA in human virus vaccines.
    Harasawa R; Tomiyama T
    J Clin Microbiol; 1994 Jun; 32(6):1604-5. PubMed ID: 8077414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells.
    Just M; Berger R; Glück R; Wegmann A
    Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds.
    Krober MS; Stracener CE; Bass JW
    JAMA; 1991 Apr; 265(16):2095-6. PubMed ID: 2013930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
    Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
    Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical safety issues of measles, mumps and rubella vaccines.
    Afzal MA; Minor PD; Schild GC
    Bull World Health Organ; 2000; 78(2):199-204. PubMed ID: 10743285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines.
    Ozaki K; Kuno-Sakai H; Kimura M
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
    JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newer viral vaccines: measles, mumps and rubella.
    Krugman S
    Schweiz Rundsch Med Prax; 1975 Feb; 64(5):124-8. PubMed ID: 1215313
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence of antibodies against measles, mumps and rubella in Israeli young adults.
    Danon YL; Adir Y; Abend I; Zaaide Y; Green MS
    Isr J Med Sci; 1992 Oct; 28(10):733-6. PubMed ID: 1399506
    [No Abstract]   [Full Text] [Related]  

  • 37. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
    Feldman S; Andrew M; Norris M; McIntyre B; Iyer R
    Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measles, mumps, and rubella vaccines.
    Wharton M; Cochi SL; Williams WW
    Infect Dis Clin North Am; 1990 Mar; 4(1):47-73. PubMed ID: 2407778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G; Peña B; Marimón JM; Pérez-Trallero E
    Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.